Cochrane Abstracts
Rituximab for thyroid‐associated ophthalmopathy
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Rituximab for Thyroid‐associated Ophthalmopathy." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/433649/all/Antidepressants_for_smoking_cessation_Edited__no_change_to_conclusions_. Accessed 24 September 2023.
Rituximab for thyroid‐associated ophthalmopathy. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433649/all/Antidepressants_for_smoking_cessation_Edited__no_change_to_conclusions_. Accessed September 24, 2023.
Rituximab for thyroid‐associated ophthalmopathy. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/433649/all/Antidepressants_for_smoking_cessation_Edited__no_change_to_conclusions_
Rituximab for Thyroid‐associated Ophthalmopathy [Internet]. In: Cochrane Abstracts. [cited 2023 September 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/433649/all/Antidepressants_for_smoking_cessation_Edited__no_change_to_conclusions_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Rituximab for thyroid‐associated ophthalmopathy
ID - 433649
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/433649/all/Antidepressants_for_smoking_cessation_Edited__no_change_to_conclusions_
DB - Evidence Central
DP - Unbound Medicine
ER -
